Mercer Global Advisors
NVCT icon

Mercer Global Advisors’s Nuvectis Pharma NVCT Stock Holding History

Mercer Global Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Buy
+1,127
New +$12.6K ﹤0.01% 4804

Other funds holding NVCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mercer Global Advisors's NVCT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 1,127 shares worth $20.7K. The stake represents ﹤0.01% of the portfolio and ranks #4804 among its holdings.

62 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Mercer Global Advisors held 1,127 shares of Nuvectis Pharma worth $20.7K as of Q2 2026.
  • Nuvectis Pharma was a new Mercer Global Advisors position in Q2 2026.
  • Nuvectis Pharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4804 holding.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.